BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care

Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) --

• Company to present results from PURE EP 2.0 Study - a multi-center, blinded, and randomized clinical trial
• Leading physicians evaluated signal data recorded during 51 cardiac ablation procedures across three medical centers of excellence

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.

BioSig’s leadership will present during the briefing, followed by a Q&A session.

Conference Call Details:
Date: Monday, July 26, 2021
Time: 2:30 PM Eastern Time (ET)
Toll-free dial-in number for U.S. callers: 877-407-8293
Toll dial-in number for U.S. and international callers: +1 201-689-8349

Webcast: https://event.webcasts.com/starthere.jsp?ei=1479482&tp_key=f08bc38a33

A replay will be available until August 9, 2021. To access the replay, please dial 877-660-6853 or 201-612-7415 in the U.S. and +1 201-612-7415 for international callers. The conference ID# is 13721285.

The Company completed enrollments in the trial in April 2021. The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1000 patient cases with the PURE EP(tm) System across twelve clinical sites.

Previously, the Company announced its plans to exhibit at the annual Heart Rhythm 2021 convention on July 28-29, 2021. BioSig’s conference program includes two clinical and scientific presentations and the demonstration of the latest software features of its PURE EP(tm) System. In addition, the Company announced that the PURE EP(tm) System would be featured during the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27, 2021.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, the PURE EP™, System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.